Answers are grounded in this paper and cite their sources.
// Maria E. Riveiro 1 , Lucile Astorgues-Xerri 1 , Ramiro Vazquez 2 , Roberta Frapolli 2 , Ivo Kwee 3, 5 , Andrea Rinaldi 3 , Elodie Odore 6 , Keyvan Rezai 6 , Mohamed Bekradda 1 , Giorgio Inghirami 7, 9 , Maurizio D’Incalci 2 , Kay Noel 10 , Esteban Cvitkovic 1, 10 , Eric Raymond 11 , Francesco Bertoni 3, 12 1 Oncology Therapeutic Development, Clichy, France 2 IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy 3 Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland 4 Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland 5 SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland 6 Radiopharmacology Department, Curie Institute - René Huguenin Hospital, Saint Cloud, France 7 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA 8 Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Turin, Turin, Italy 9 Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA 10 Oncoethix SA (now Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp and Dohme Corp.), Lucerne, Switzerland 11 Medical Oncology Department, CHUV, Lausanne, Switzerland 12 Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland Correspondence to: Maria E Riveiro, email: eugenia.riveiro@oncotd.com Keywords: OTX015 (MK-8628), bromodomain, NSCLC, SCLC, KRAS Received: January 21, 2016 Accepted: October 14, 2016 Published: November 07, 2016 ABSTRACT Inhibitors targeting epigenetic control points of oncogenes offer a potential mean of blocking tumor progression in small cell and non-small cell lung carcinomas (SCLC, NSCLC). OTX015 (MK-8628) is a BET inhibitor selectively blocking BRD2/3/4. OTX015 was evaluated in a panel of NSCLC or SCLC models harboring different oncogenic mutations. Cell proliferation inhibition and cell cycle arrest were seen in sensitive NSCLC cells. MYC and MYCN were downregulated at both the mRNA and protein levels. In addition, OTX015-treatment significantly downregulated various stemness cell markers, including NANOG, Musashi-1, CD113 and EpCAM in H3122-tumors in vivo . Conversely, in SCLC models, weak antitumor activity was observed with OTX015, both in vitro and in vivo . No predictive biomarkers of OTX015 activity were identified in a large panel of candidate genes known to be affected by BET inhibition. In NSCLC models, OTX015 was equally active in both EML4-ALK positive and negative cell lines, whereas in SCLC models the presence of functional RB1 protein, which controls cell progression at G1, may be related to the final biological outcome of OTX015. Gene expression profiling in NSCLC and SCLC cell lines showed that OTX015 affects important genes and pathways with a very high overlapping between both sensitive and resistant cell lines. These data support the rationale for the OTX015 Phase Ib (NCT02259114) in solid tumors, where NSCLC patients with rearranged ALK gene or KRAS-positive mutations are currently being treated.
No takes yet. Share an insight, caveat, or question.
Riveiro et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: